Dusseldorf - Delayed Quote EUR

CStone Pharmaceuticals (PH4.DU)

0.3220

+0.0180

+(5.92%)

At close: April 23 at 7:30:39 PM GMT+2

CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual results and recent business updates.

PR Newswire 27 days ago

CSPHF
CStone to Showcase Five Latest Research Achievements at AACR 2025

From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific antibody CS2009, the bispecific antibody CS2011, and three novel antibody-drug conjugates (ADCs) developed from CStone's proprietary ADC platform: CS5006, CS5007, and CS5005. The abstracts will be published in Cancer Research, the official journal

PR Newswire 29 days ago

CSPHF
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. The application seeks approval for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following concurrent or sequential platinum-based chemoradiotherapy (CRT). This marks CStone's second

PR Newswire last month

CSPHF
CStone Pharmaceuticals Leads Our Top 3 Global Penny Stock Picks

As global markets grapple with inflation concerns and trade policy uncertainties, investors are seeking opportunities that can navigate these challenges. Penny stocks, a term that may seem outdated, still represent an intriguing investment area for those interested in smaller or newer companies. These stocks can offer surprising value and potential for significant returns when backed by solid financial foundations.

Simply Wall St. last month

CSPHF
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application in Australia for CS5001, its ROR1-targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for DLBCL. CS5001 is also being evaluated as both a monotherapy and in combination with a PD-L1 inhibitor for advanced solid tumors in an ongoing global multi-center clini

PR Newswire last month

CSPHF
CStone doses first subject in trial of CS2009 for advanced solid tumours

The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.

Clinical Trials Arena last month

CSPHF
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed.

PR Newswire last month

CSPHF
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced the publication of the GEMSTONE-303 study results for sugemalimab (brand name: Cejemly®) in the prestigious Journal of the American Medical Association (JAMA) .

PR Newswire last month

CSPHF
February 2025 Penny Stocks Worth Watching

As global markets edge toward record highs, driven by U.S. stock indexes and a surge in the Nasdaq Composite, investors are navigating a landscape marked by rising inflation and cautious monetary policy. In this context, penny stocks—often smaller or newer companies—remain an intriguing investment area despite the term's dated connotation. These stocks can offer growth opportunities when backed by strong financials, presenting potential for significant returns as they reveal hidden value in...

Simply Wall St. 2 months ago

CHJTF

CSPCY

CHNVF
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key product, Cejemly® (sugemalimab), has been included in the European Society for Medical Oncology (ESMO) Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer (NSCLC) Living Guideline. Sugemalimab is recommended as a first-line combination therapy for both squamous and non-squamous NSCLC, with substantial

PR Newswire 2 months ago

CSPHF
CStone Partners with SteinCares to Market Sugemalimab in Latin America

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced a strategic commercialization partnership with SteinCares, a leading pharmaceutical company with over 40 years of experience and a strong presence in Latin America. Under this agreement, SteinCares will gain the commercialization rights for sugemalimab in 10 LATAM countries, including Brazil, Argentina, Mexico, Chile, Colo

PR Newswire 2 months ago

CSPHF
January 2025's Promising Penny Stocks

Global markets have shown resilience, with major U.S. stock indexes rebounding and value stocks outperforming growth shares, driven by easing core inflation and strong bank earnings. In the context of this positive market momentum, penny stocks—often smaller or newer companies—remain a niche yet promising area for investors seeking growth opportunities. While the term 'penny stock' may seem outdated, these investments can still offer significant potential when backed by solid financial health...

Simply Wall St. 3 months ago

CSPHF

2158.HK
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of clinical trial application in Australia for CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a leading asset from the Company's Pipeline 2.0 to address various solid tumors. This first-in-human study has also been registered and published on Clinicaltrials.gov (NCT number: NCT06741644).

PR Newswire 3 months ago

CSPHF
Infinity Logistics and Transport Ventures Among 3 Promising Penny Stocks

As global markets navigate a landscape marked by interest rate cuts from the ECB and SNB, and anticipation of further Fed action, investors are witnessing mixed performances across major indices. In this context, penny stocks—often associated with smaller or newer companies—continue to capture attention due to their unique blend of affordability and potential for growth. While the term may seem outdated, these stocks remain relevant as they can offer compelling opportunities when backed by...

Simply Wall St. 4 months ago

CSPHF

1483.HK

1442.HK
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the presentation of the latest clinical data for CS5001, an anti-ROR1 ADC and one of the leading assets in CStone Pipeline 2.0, at the 66th American Society of Hematology (ASH) Annual Meeting. These data highlight the compound's potential as a treatment for lymphoma.

PR Newswire 4 months ago

CSPHF
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab in combination with platinum-based chemotherapy as a first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) without EGFR-sensitive mutations or ALK, ROS1, RET genomic alterations. This marks the second

PR Newswire 5 months ago

CSPHF
High Growth Tech Stocks In Hong Kong To Watch This September 2024

With global markets reacting positively to China's robust stimulus measures, Hong Kong's Hang Seng Index has seen a significant uptick, reflecting renewed investor confidence. In this favorable economic climate, identifying high-growth tech stocks becomes crucial for investors looking to capitalize on market momentum and technological advancements.

Simply Wall St. 6 months ago

CSPHF

KSHTY

KUASF
High Growth Tech Stocks In Hong Kong Featuring SUNeVision Holdings And Two Others

The Hong Kong market has recently experienced mixed performance, with the Hang Seng Index gaining 2.14% amid broader global economic uncertainties and fluctuating investor sentiment. As inflation data and economic indicators continue to influence market dynamics, high-growth tech stocks in Hong Kong present intriguing opportunities for investors seeking to navigate these volatile conditions. In this article, we will explore three promising tech stocks in Hong Kong, starting with SUNeVision...

Simply Wall St. 7 months ago

CSPHF

NDWTY

1686.HK
CStone Reports 2024 Interim Results and Recent Corporate Updates

CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today reported interim financial results for 2024 and recent business highlights.

PR Newswire 7 months ago

CSPHF
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the European Commission (EC) has approved sugemalimab (Brand name: Cejemly®) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Sugemal

PR Newswire 8 months ago

CSPHF

Performance Overview

Return	PH4.DU	HANG SENG INDEX (^HSI)
YTD	+25.78%	+8.70%
1-Year	+226.90%	+26.77%
3-Year	-43.01%	+5.65%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CStone Pharmaceuticals (PH4.DU)

CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

CStone to Showcase Five Latest Research Achievements at AACR 2025

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

CStone Pharmaceuticals Leads Our Top 3 Global Penny Stock Picks

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

CStone doses first subject in trial of CS2009 for advanced solid tumours

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

February 2025 Penny Stocks Worth Watching

CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline

CStone Partners with SteinCares to Market Sugemalimab in Latin America

January 2025's Promising Penny Stocks

CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody

Infinity Logistics and Transport Ventures Among 3 Promising Penny Stocks

Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting

CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

High Growth Tech Stocks In Hong Kong To Watch This September 2024

High Growth Tech Stocks In Hong Kong Featuring SUNeVision Holdings And Two Others

CStone Reports 2024 Interim Results and Recent Corporate Updates

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

Performance Overview